002019 亿帆医药
交易中 09-15 13:22:27
资讯
新帖
简况
公司问答丨亿帆医药：公司胰岛素在研项目实施地点在波兰 前期受旅行限制影响 整体研发进度确实与预期存在一些偏差
格隆汇 · 09-14 16:45
公司问答丨亿帆医药：公司胰岛素在研项目实施地点在波兰 前期受旅行限制影响 整体研发进度确实与预期存在一些偏差
股市必读：亿帆医药新发布《第九届董事会第七次（临时）会议决议公告》
证券之星 · 09-14 00:58
股市必读：亿帆医药新发布《第九届董事会第七次（临时）会议决议公告》
亿帆医药（002019）披露2026年半年度报告，8月31日股价下跌2.49%
证券之星 · 08-31
亿帆医药（002019）披露2026年半年度报告，8月31日股价下跌2.49%
亿帆医药（002019）2026年中报简析：净利润同比下降32.48%
证券之星 · 08-30
亿帆医药（002019）2026年中报简析：净利润同比下降32.48%
亿帆医药(002019)8月10日股东户数4.71万户，较上期增加0.74%
证券之星 · 08-29
亿帆医药(002019)8月10日股东户数4.71万户，较上期增加0.74%
图解亿帆医药中报：第二季度单季净利润同比下降34.75%
证券之星 · 08-29
图解亿帆医药中报：第二季度单季净利润同比下降34.75%
亿帆医药(002019)8月10日股东户数4.71万户，较上期增加0.74%
证券之星 · 08-26
亿帆医药(002019)8月10日股东户数4.71万户，较上期增加0.74%
亿帆医药：经营性现金流充足，发债是为优化公司的债务结构
证券之星 · 08-26
亿帆医药：经营性现金流充足，发债是为优化公司的债务结构
亿帆医药：通过自研、引进和合作研发等方式加快产品线布局
证券之星 · 08-26
亿帆医药：通过自研、引进和合作研发等方式加快产品线布局
亿帆医药：截止2026年8月10日公司股东人数为47,101人
证券之星 · 08-26
亿帆医药：截止2026年8月10日公司股东人数为47,101人
亿帆医药：目前海外在售的国家包括美国、德国和斯洛文尼亚
证券之星 · 08-26
亿帆医药：目前海外在售的国家包括美国、德国和斯洛文尼亚
股市必读：亿帆医药新发布《关于收到中国银行间市场交易商协会《接受注册通知书》的公告》
证券之星 · 08-17
股市必读：亿帆医药新发布《关于收到中国银行间市场交易商协会《接受注册通知书》的公告》
亿帆医药(002019)7月31日股东户数4.68万户，较上期减少0.46%
证券之星 · 08-12
亿帆医药(002019)7月31日股东户数4.68万户，较上期减少0.46%
亿帆医药：硫酸长春新碱注射液授权欧盟等多国商业化
证券之星 · 08-12
亿帆医药：硫酸长春新碱注射液授权欧盟等多国商业化
亿帆医药：在研项目断金胶囊目前尚无节点性进展
证券之星 · 08-12
亿帆医药：在研项目断金胶囊目前尚无节点性进展
亿帆医药：截止2026年7月10日公司股东人数为46,971人
证券之星 · 08-12
亿帆医药：截止2026年7月10日公司股东人数为46,971人
亿帆医药：2’-FL产品已经在开始生产与部分销售了
证券之星 · 08-12
亿帆医药：2’-FL产品已经在开始生产与部分销售了
股市必读：亿帆医药新发布《关于回购公司股份的进展公告》
证券之星 · 08-06
股市必读：亿帆医药新发布《关于回购公司股份的进展公告》
亿帆医药（002019）披露回购公司股份进展公告，8月4日股价下跌0.1%
证券之星 · 08-04
亿帆医药（002019）披露回购公司股份进展公告，8月4日股价下跌0.1%
亿帆医药（002019）披露首次回购公司股份公告，7月16日股价上涨4.68%
证券之星 · 07-16
亿帆医药（002019）披露首次回购公司股份公告，7月16日股价上涨4.68%
加载更多
公司概况
公司名称：
亿帆医药股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-13
主营业务：
亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是医药自有产品（含进口）、医药其他产品、医药服务、维生素、高分子材料。
发行价格：
12.57
{"stockData":{"symbol":"002019","market":"SZ","secType":"STK","nameCN":"亿帆医药","latestPrice":9.23,"timestamp":1789449747000,"preClose":9.31,"halted":0,"volume":2672610,"delay":0,"changeRate":-0.0086,"floatShares":843000000,"shares":1216000000,"eps":0.2495,"marketStatus":"交易中","change":-0.08,"latestTime":"09-15 13:22:27","open":9.31,"high":9.35,"low":9.22,"amount":24772900,"amplitude":0.014,"askPrice":9.24,"askSize":54,"bidPrice":9.23,"bidSize":373,"shortable":0,"etf":0,"ttmEps":0.2495,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789455600000},"marketStatusCode":2,"adr":0,"adjPreClose":9.31,"symbolType":"stock","openAndCloseTimeList":[[1789435800000,1789443000000],[1789448400000,1789455600000]],"highLimit":10.24,"lowLimit":8.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1216390085,"isCdr":false,"pbRate":1.28,"roa":"--","peRate":36.993988,"roe":"2.3%","epsLYR":0.33,"committee":0.191458,"marketValue":11227000000,"turnoverRate":0.0032,"status":1,"floatMarketCap":7776000000},"requestUrl":"/m/hq/s/002019/","defaultTab":"news","newsList":[{"id":"2667659066","title":"公司问答丨亿帆医药：公司胰岛素在研项目实施地点在波兰 前期受旅行限制影响 整体研发进度确实与预期存在一些偏差","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659066","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659066?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:45","pubTimestamp":1789375507,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002019","BK0070","BK0197","BK0077","BK0239","BK0185","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667093687","title":"股市必读：亿帆医药新发布《第九届董事会第七次（临时）会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667093687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667093687?lang=zh_cn&edition=full","pubTime":"2026-09-14 00:58","pubTimestamp":1789318693,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，亿帆医药报收于9.2元，下跌2.75%，换手率1.44%，成交量12.16万手，成交额1.13亿元。当日关注点交易信息汇总：9月11日主力资金净流出3189.76万元，占总成交额28.33%。公司公告汇总：亿帆医药董事会审议通过全资子公司出资10,000万元参与设立规模33.5亿元的股权投资基金，投向新兴产业，资金来源为自有资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","BK0077","BK0070","BK0191","BK0197","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071893","title":"亿帆医药（002019）披露2026年半年度报告，8月31日股价下跌2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071893","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071893?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:45","pubTimestamp":1788169548,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，亿帆医药报收于9.78元，较前一交易日下跌2.49%，最新总市值为118.96亿元。该股当日开盘9.85元，最高9.89元，最低9.75元，成交额达1.37亿元，换手率为1.66%。近日，亿帆医药披露《2026年半年度报告》。报告显示，报告期内公司实现营业收入2,467,572,376.09元，同比下降6.36%；归属于上市公司股东的净利润为205,025,090.84元，同比下降32.48%；扣除非经常性损益后的净利润为202,970,414.71元，同比下降14.43%。经营活动产生的现金流量净额为593,510,064.14元，同比增长107.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0197","BK0239","BK0191","BK0070","BK0185","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048213","title":"亿帆医药（002019）2026年中报简析：净利润同比下降32.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048213?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:22","pubTimestamp":1788042165,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亿帆医药发布2026年中报。根据财报显示，亿帆医药净利润同比下降32.48%。截至本报告期末，公司营业总收入24.68亿元，同比下降6.36%，归母净利润2.05亿元，同比下降32.48%。按单季度数据看，第二季度营业总收入12.12亿元，同比下降7.37%，第二季度归母净利润9819.78万元，同比下降34.75%。去年的净利率为7.28%，算上全部成本后，公司产品或服务的附加值一般。本文数据来源于亿帆医药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012636","title":"亿帆医药(002019)8月10日股东户数4.71万户，较上期增加0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012636","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012636?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:13","pubTimestamp":1787994804,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年8月10日公司股东户数为4.71万户，较7月31日增加347.0户，增幅为0.74%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至8月10日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年7月31日至2026年8月10日，亿帆医药区间涨幅为0.78%，在此期间股东户数增加347.0户，增幅为0.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0197","BK0070","BK0185","002019","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663226018","title":"图解亿帆医药中报：第二季度单季净利润同比下降34.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663226018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663226018?lang=zh_cn&edition=full","pubTime":"2026-08-29 02:45","pubTimestamp":1787942735,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药2026年中报显示，上半年度公司主营收入24.68亿元，同比下降6.36%；归母净利润2.05亿元，同比下降32.48%；扣非净利润2.03亿元，同比下降14.43%；其中2026年第二季度，公司单季度主营收入12.12亿元，同比下降7.37%；单季度归母净利润9819.78万元，同比下降34.75%；单季度扣非净利润9886.81万元，同比下降30.3%；负债率32.6%，投资收益-1222.52万元，财务费用4099.09万元，毛利率46.76%。财报数据概要请见下图:本文数据来源于亿帆医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794769","title":"亿帆医药(002019)8月10日股东户数4.71万户，较上期增加0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662794769?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:40","pubTimestamp":1787737257,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年8月10日公司股东户数为4.71万户，较7月31日增加347.0户，增幅为0.74%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至8月10日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年7月31日至2026年8月10日，亿帆医药区间涨幅为0.78%，在此期间股东户数增加347.0户，增幅为0.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600039779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002019","BK0239","BK0191","BK0077","BK0070","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662407795","title":"亿帆医药：经营性现金流充足，发债是为优化公司的债务结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2662407795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662407795?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:06","pubTimestamp":1787731569,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是不是现金流严重不足，回购要贷款，还要借钱20亿。是主业现金流不足？亿帆医药回复：感谢您的关注与提问。经营性现金流充足，发债是为优化公司的债务结构。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600033863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0070","159399","002019","BK0077","BK0191","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662951267","title":"亿帆医药：通过自研、引进和合作研发等方式加快产品线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2662951267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662951267?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:00","pubTimestamp":1787731244,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问根据公司现状和未来储备情况分析，公司会不会出现后续创新药青黄不接，在售药品营收停滞不前的局面？谢谢！亿帆医药回复：理解您的担忧。公司将在提高研发效率的基础上通过自研、引进和合作研发等方式加快产品线布局；另一方面，公司将在稳固基本盘的情况下，同时做好出海与渠道的双突破。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600033298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0070","BK0191","BK0239","BK0197","002019","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795119","title":"亿帆医药：截止2026年8月10日公司股东人数为47,101人","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795119?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:00","pubTimestamp":1787731243,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止8月10日，公司最新股东人数是多少？亿帆医药回复：您好，截止2026年8月10日公司股东人数为47,101人。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600033296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0191","BK0070","BK0077","002019","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795141","title":"亿帆医药：目前海外在售的国家包括美国、德国和斯洛文尼亚","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795141?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:00","pubTimestamp":1787731242,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：f627出海目前为止仍只在美国销售，请问该药国外销售是不是没戏了？谢谢！亿帆医药回复：感谢您的关注与提问。目前海外在售的国家包括美国、德国和斯洛文尼亚。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600033294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","FDXSmain","FDXMmain","BK0070","BK0191","002019","FDAXmain","BK0185","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660170926","title":"股市必读：亿帆医药新发布《关于收到中国银行间市场交易商协会《接受注册通知书》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170926?lang=zh_cn&edition=full","pubTime":"2026-08-17 02:12","pubTimestamp":1786903932,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，亿帆医药报收于10.61元，下跌0.56%，换手率2.25%，成交量18.98万手，成交额2.03亿元。当日关注点交易信息汇总：8月14日主力资金净流入530.47万元，占总成交额2.62%。公司公告汇总：公司于8月14日收到交易商协会《接受注册通知书》，获准注册20亿元中期票据，有效期2年，由兴业银行主承销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0278","IE00B19Z5X02.USD","03143","LU1224444064.USD","BK0012","LU2039709279.SGD","LU1497734951.SGD","LU2097828714.EUR","BK0239","LU1522347837.USD","HK0000286598.CNH","LU1497733557.USD","LU0293314216.USD","LU1634259557.SGD","LU1497733631.SGD","LU1813983027.USD","IE00BWDBJ730.SGD","LU1048588211.SGD","601988","BK1560","LU0588546209.SGD","IE00BQJZWZ67.USD","LU0651947912.USD","BK0015","BK0070","BK1521","LU2097828805.USD","BK0183","LU0651946864.USD","BK0028","LU0072462343.USD","BK0191","SG9999004220.SGD","SG9999006597.SGD","LU0314109678.HKD","LU1328277881.USD","LU1515016050.SGD","LU1634259391.SGD","LU2097828557.USD","LU1282651121.HKD","03988","BK0077","SG9999001093.SGD","LU2097828631.EUR","002019","BK1231","LU1282651048.USD","LU0307460666.USD","LU1051768304.USD","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973977","title":"亿帆医药(002019)7月31日股东户数4.68万户，较上期减少0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973977","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658973977?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:24","pubTimestamp":1786526685,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年7月31日公司股东户数为4.68万户，较7月10日减少217.0户，减幅为0.46%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年7月10日至2026年7月31日，亿帆医药区间涨幅为4.05%，在此期间股东户数减少217.0户，减幅为0.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200029392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0070","BK0077","BK0197","BK0185","002019","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658924455","title":"亿帆医药：硫酸长春新碱注射液授权欧盟等多国商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2658924455","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658924455?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:06","pubTimestamp":1786518381,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司下一步会不会进一步把自己的系列中成药、化药产品在哈萨克斯坦、乌兹别克斯坦等中亚国家推广销售？亿帆医药回复：感谢您的关注与提问。不仅仅局限于中亚，比如近期公司将境内生产的硫酸长春新碱注射液在欧盟（其中11个成员国）、英国、挪威、巴西和部分东南亚（马来西亚、新加坡和文莱）市场授权给合作伙伴进行商业化。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200020371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","002019","FESXmain","FSXEmain","BK0191","BK0197","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692448","title":"亿帆医药：在研项目断金胶囊目前尚无节点性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658692448?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:06","pubTimestamp":1786518381,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的断金戒毒胶囊的II期临床试验最近有什么新的进展吗？亿帆医药回复：感谢您的关注与提问。在研项目断金胶囊目前尚无节点性进展。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200020374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0197","BK0239","BK0191","BK0070","BK0185","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658924107","title":"亿帆医药：截止2026年7月10日公司股东人数为46,971人","url":"https://stock-news.laohu8.com/highlight/detail?id=2658924107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658924107?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:06","pubTimestamp":1786518380,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止7月10日公司最新股东人数亿帆医药回复：您好，截止2026年7月10日公司股东人数为46,971人。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200020367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0191","BK0070","BK0077","002019","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658492446","title":"亿帆医药：2’-FL产品已经在开始生产与部分销售了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658492446","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658492446?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:06","pubTimestamp":1786518380,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：鑫福HMOs的生产许可证拿到手了，最近会开始生产和销售吗？是只在国内销售还是同时也出口？亿帆医药回复：感谢您的关注与提问。2’-FL产品已经在开始生产与部分销售了。同时，目前正推进下游客户验厂及商务谈判。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200020372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0185","BK0239","BK0197","BK0077","BK0191","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657850521","title":"股市必读：亿帆医药新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657850521","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657850521?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:17","pubTimestamp":1785950231,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，亿帆医药报收于10.22元，下跌1.26%，换手率1.23%，成交量10.38万手，成交额1.06亿元。公司公告汇总：截至7月31日，亿帆医药已回购股份500万股，成交总金额5,394.36万元，占总股本0.41%。公司公告汇总关于回购公司股份的进展公告亿帆医药于2026年5月27日和6月12日分别召开董事会及临时股东大会，审议通过回购公司股份并用于注销的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002019","BK0185","BK0070","BK0191","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555215","title":"亿帆医药（002019）披露回购公司股份进展公告，8月4日股价下跌0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656555215?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:29","pubTimestamp":1785853754,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，亿帆医药报收于10.35元，较前一交易日下跌0.1%，最新总市值为125.9亿元。该股当日开盘10.37元，最高10.48元，最低10.3元，成交额达9385.59万元，换手率为1.07%。近日，亿帆医药股份有限公司发布关于回购公司股份的进展公告。公告显示，公司于2026年5月27日和6月12日分别召开董事会及临时股东大会，审议通过回购公司股份并用于注销的议案。本次回购符合相关法规及公司方案要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0191","002019","BK0239","BK0185","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440438","title":"亿帆医药（002019）披露首次回购公司股份公告，7月16日股价上涨4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440438","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651440438?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:10","pubTimestamp":1784211028,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，亿帆医药报收于10.95元，较前一交易日上涨4.68%，最新总市值为133.19亿元。该股当日开盘10.4元，最高11.05元，最低10.28元，成交额达4.17亿元，换手率为4.61%。近日，亿帆医药披露《关于首次回购公司股份的公告》。本次回购符合公司既定方案及相关法律法规要求。公司后续将根据市场情况在回购期限内继续实施回购计划，并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0197","BK0077","BK0070","002019","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789449751492,"stockEarnings":[{"period":"1week","weight":-0.0392},{"period":"1month","weight":-0.1225},{"period":"3month","weight":-0.0624},{"period":"6month","weight":-0.33},{"period":"1year","weight":-0.364},{"period":"ytd","weight":-0.214}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"亿帆医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47079人(较上一季度减少0.05%)","perCapita":"17895股","listingDate":"2004-07-13","address":"浙江省杭州市临安区临安经济开发区","registeredCapital":"121639万元","survey":" 亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是医药自有产品（含进口）、医药其他产品、医药服务、维生素、高分子材料。","listedPrice":12.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亿帆医药,002019,亿帆医药股票,亿帆医药股票老虎,亿帆医药股票老虎国际,亿帆医药行情,亿帆医药股票行情,亿帆医药股价,亿帆医药股市,亿帆医药股票价格,亿帆医药股票交易,亿帆医药股票购买,亿帆医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}